297 related articles for article (PubMed ID: 30694842)
21. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
Chan IS; Bhatia S; Kaufman HL; Lipson EJ
J Immunother Cancer; 2018 Mar; 6(1):23. PubMed ID: 29566749
[TBL] [Abstract][Full Text] [Related]
23. Advances in Merkel cell carcinoma from a pathologist's perspective.
Barksdale SK
Pathology; 2017 Oct; 49(6):568-574. PubMed ID: 28844339
[TBL] [Abstract][Full Text] [Related]
24. Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.
Principe DR; Clark JI; Emami B; Borowicz S
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31439556
[TBL] [Abstract][Full Text] [Related]
25. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
26. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs.
Schadendorf D; Lebbé C; Zur Hausen A; Avril MF; Hariharan S; Bharmal M; Becker JC
Eur J Cancer; 2017 Jan; 71():53-69. PubMed ID: 27984768
[TBL] [Abstract][Full Text] [Related]
27. Merkel cell carcinoma.
Becker JC; Stang A; DeCaprio JA; Cerroni L; Lebbé C; Veness M; Nghiem P
Nat Rev Dis Primers; 2017 Oct; 3():17077. PubMed ID: 29072302
[TBL] [Abstract][Full Text] [Related]
28. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
29. Molecular and immune targets for Merkel cell carcinoma therapy and prevention.
Cohen L; Tsai KY
Mol Carcinog; 2019 Sep; 58(9):1602-1611. PubMed ID: 31116890
[TBL] [Abstract][Full Text] [Related]
30. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
31. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.
Bhatia S; Afanasiev O; Nghiem P
Curr Oncol Rep; 2011 Dec; 13(6):488-97. PubMed ID: 21953511
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
33. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.
Munhoz RR; Cayol F; Corrales L; Gerson R; Tilli M; Barreto EO; Sánchez Castillo JO; Schmerling RA; Cinat G
Cancer Immunol Immunother; 2021 Apr; 70(4):1031-1036. PubMed ID: 33104838
[TBL] [Abstract][Full Text] [Related]
34. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract][Full Text] [Related]
35. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
36. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.
Spada F; Bossi P; Caracò C; Sileni VC; Dei Tos AP; Fazio N; Grignani G; Maio M; Quaglino P; Queirolo P; Ascierto PA;
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35701070
[TBL] [Abstract][Full Text] [Related]
37. Merkel cell carcinoma.
Han SY; North JP; Canavan T; Kim N; Yu SS
Hematol Oncol Clin North Am; 2012 Dec; 26(6):1351-74. PubMed ID: 23116583
[TBL] [Abstract][Full Text] [Related]
38. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
39. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
40. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
